Global Information
회사소개 | 문의 | 위시리스트

세계의 털세포 백혈병 치료제 시장(2019-2023년)

Global Hairy Cell Leukemia Therapeutics Market 2019-2023

리서치사 TechNavio (Infiniti Research Ltd.)
발행일 2019년 07월 상품 코드 900616
페이지 정보 영문 129 Pages
가격
US $ 2,500 ₩ 3,001,000 PDF by E-mail (Single User License) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 3,000 ₩ 3,601,000 PDF by E-mail (5-user License) help
동일 사업장 내 5명까지 공유하여 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 4,000 ₩ 4,802,000 PDF by E-mail (Enterprise License) help
동일 기업 내 모든 분들이 공유하여 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 5,000 ₩ 6,002,000 PDF by E-mail (Global License) help
동일 기업 내 모든 분들이 공유하여 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다. 또한 해당 라이선스는 보고서 컨텐츠의 15% 이내로 외부용 문서에 인용 게재가 허용됩니다(예:프레스릴리스, 마케팅 자료, 백서 등).


세계의 털세포 백혈병 치료제 시장(2019-2023년) Global Hairy Cell Leukemia Therapeutics Market 2019-2023
발행일 : 2019년 07월 페이지 정보 : 영문 129 Pages

털세포 백혈병은 백혈병 중에서도 희귀하고 진행이 늦은 아류형이며, 백혈병 전체 증례의 약 2%를 차지하고 있습니다. 세계 털세포 백혈병 치료제 시장은 2018년 화학요법 부문의 시장 점유율이 높았고, 이러한 경향은 예측기간 동안 계속될 것으로 예상됩니다. 또 털세포 백혈병 치료제 시장은 털세포 백혈병으로 연결되는 유해물질 노출 증가, 고령자 인구 증가, 전략적 제휴 등이 성장 촉진요인이 되어 예측기간 중 6% 이상의 연평균 복합 성장률(CAGR)로 확대될 전망입니다. 그러나 한정적인 환자 집단, 화학요법제의 부작용, 어려운 진단 등이 예측기간 동안 털세포 백혈병 치료 시장의 성장을 방해할 가능성이 있습니다.

세계의 털세포 백혈병 치료제(Hairy Cell Leukemia Therapeutics) 시장에 대해 조사 분석했으며, 시장 규모 및 성장률, 시장 동향, 시장 성장 촉진요인과 과제, 시장 기회, 주요 벤더 등에 대한 체계적인 정보를 제공합니다.

목차

제1장 주요 요약

제2장 조사 범위

  • 서론 1
  • 서론 2
  • 달러의 통화 환산율

제3장 시장 상황

  • 시장 생태계
  • 시장의 특징
  • 시장 세분화 분석

제4장 시장 규모

  • 시장 정의
  • 시장 규모(2018년)
  • 시장 규모 및 예측(2018-2023년)

제5장 Five Forces 분석

  • 구매자의 협상력
  • 공급업체의 협상력
  • 신규 참여업체의 위협
  • 대용품의 위협
  • 경쟁사의 위협
  • 시장 현황

제6장 시장 세분화 : 제품별

  • 시장 세분화 : 제품별
  • 제품별 비교 : 시장 규모 및 예측(2018-2023년)
  • 화학요법
  • 표적요법
  • 시장 기회 : 제품별

제7장 고객 상황

제8장 지역별 상황

  • 지역별 세분화
  • 지역별 비교 : 시장 규모 및 예측(2018-2023년)
  • 북미
  • 유럽
  • 아시아
  • 기타 지역
  • 주요 국가
  • 시장 기회

제9장 의사결정 프레임워크

제10장 성장요인과 과제

  • 시장 성장요인
  • 시장의 과제

제11장 시장 동향

  • 혈액암 연구비 증가
  • 새로운 치료법의 등장
  • 특수 의약품 지정

제12장 벤더 상황

  • 개요
  • 파괴적 혁신
  • 경쟁 시나리오

제13장 벤더 분석

  • 대상 벤더
  • 벤더 분류
  • 벤더의 시장 포지셔닝
  • AstraZeneca Plc
  • F. Hoffmann-La Roche Ltd.
  • Merck & Co., Inc.
  • Mylan NV
  • Pfizer Inc.

제14장 부록

  • 조사 방법
  • 약어 리스트
  • 벤더의 시장 포지셔닝 정의

제15장 TECHNAVIO에 대해

LSH 19.08.13

About this market

Hairy cell leukemia is a rare, slow-growing subtype of leukemia, which accounts for about 2% of the total cases of leukemia. Technavio's hairy cell leukemia therapeutics analysis considers sales from both chemotherapies and targeted therapy. Our analysis also considers the sales of hairy cell leukemia therapeutics in North America, Europe, Asia, and the rest of the world (ROW). In 2018, the chemotherapy segment had a significant market share, and this trend is expected to continue over the forecast period. Factors such as the increasing prevalence of leukemia, including hairy cell leukemia, will play a significant role in the chemotherapy segment to maintain its market position. Also, our global hairy cell leukemia therapeutics market report looks at factors such as increased exposure to hazardous substances leading to hairy cell leukemia, growing geriatric population, strategic alliances. However, limited patient pool, adverse effects of chemotherapy drugs, difficulty in diagnosis may hamper the growth of the hairy cell leukemia therapeutics industry over the forecast period.

Overview

Increasing exposure to hazardous substances leading to hairy cell leukemia

Exposure to such hazardous substances can happen due to various types of occupations such as farming, working in manufacturing plants dealing with hazardous chemicals and fumes, and working in coal mines, cement- and gravel-producing plants. Exposure to chemical fertilizers and pesticides is continuously increasing as the lack of nutrients in the soil has increased the use of fertilizers to provide required nutrients and to improve agriculture yields. Thus, to meet the food demand of the ever-increasing population, chemical fertilizers are increasingly used, which is expected to increase the prevalence of hairy cell leukemia which, in turn, will lead the expansion of the global hairy cell leukemia therapeutics market at a CAGR of over 6% during the forecast period.

Advent of novel therapies

The global hairy cell leukemia therapeutics market has been witnessing some advances in research since the beginning of the 21st century, which have led to the launch of a few novel therapies for the treatment of hairy cell leukemia and other hematologic malignancies. The strong prevalence of various types of blood cancer at the global level has necessitated the need for the development of advanced therapies, such as kinase inhibitors and gene therapies, to treat such conditions. Such advents of novel therapies are likely to offset the challenges posed by the adverse effects of chemotherapy drugs in the future: which will contribute to the growth of the market during the forecast period.

For the detailed list of factors that will drive the global hairy cell leukemia therapeutics market during the forecast period 2019-2023, view our report.

Competitive Landscape

With the presence of several major players, the global hairy cell leukemia therapeutics market is concentrated. Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading hairy cell leukemia therapeutics manufacturers, that include AstraZeneca Plc, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Mylan NV, and Pfizer Inc.

Also, the hairy cell leukemia therapeutics market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage on all forthcoming growth opportunities.

TABLE OF CONTENTS

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

  • 2.1 Preface
  • 2.2 Preface
  • 2.3 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 04: MARKET SIZING

  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 06: MARKET SEGMENTATION BY PRODUCT

  • Market segmentation by product
  • Comparison by product
  • Chemotherapy - Market size and forecast 2018-2023
  • Targeted therapy - Market size and forecast 2018-2023
  • Market opportunity by product

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE

  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2018-2023
  • Europe - Market size and forecast 2018-2023
  • Asia - Market size and forecast 2018-2023
  • ROW - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity

PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 11: MARKET TRENDS

  • Increasing research grants for blood cancers
  • Advent of novel therapies
  • Special drug designations

PART 12: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption
  • Competitive scenario

PART 13: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • AstraZeneca Plc
  • F. Hoffmann-La Roche Ltd.
  • Merck & Co., Inc.
  • Mylan NV
  • Pfizer Inc.

PART 14: APPENDIX

  • Research methodology
  • List of abbreviations
  • Definition of market positioning of vendors

PART 15: EXPLORE TECHNAVIO

List of Exhibits

  • Exhibit 01: Product overview
  • Exhibit 02: Global pharmaceuticals market
  • Exhibit 03: Segments of global pharmaceuticals market
  • Exhibit 04: Market characteristics
  • Exhibit 05: Market segments
  • Exhibit 06: Market definition - Inclusions and exclusions checklist
  • Exhibit 07: Market size 2018
  • Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions)
  • Exhibit 09: Global market: Year-over-year growth 2019-2023 (%)
  • Exhibit 10: Five forces analysis 2018
  • Exhibit 11: Five forces analysis 2023
  • Exhibit 12: Bargaining power of buyers
  • Exhibit 13: Bargaining power of suppliers
  • Exhibit 14: Threat of new entrants
  • Exhibit 15: Threat of substitutes
  • Exhibit 16: Threat of rivalry
  • Exhibit 17: Market condition - Five forces 2018
  • Exhibit 18: Product - Market share 2018-2023 (%)
  • Exhibit 19: Comparison by product
  • Exhibit 20: Chemotherapy - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 21: Chemotherapy - Year-over-year growth 2019-2023 (%)
  • Exhibit 22: Targeted therapy - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 23: Targeted therapy - Year-over-year growth 2019-2023 (%)
  • Exhibit 24: Patient assistance programs
  • Exhibit 25: Market opportunity by product
  • Exhibit 26: Customer landscape
  • Exhibit 27: Market share by geography 2018-2023 (%)
  • Exhibit 28: Geographic comparison
  • Exhibit 29: North America - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 30: North America - Year-over-year growth 2019-2023 (%)
  • Exhibit 31: Top 3 countries in North America
  • Exhibit 32: Europe - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 33: Europe - Year-over-year growth 2019-2023 (%)
  • Exhibit 34: Top 3 countries in Europe
  • Exhibit 35: Asia - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 36: Proportion of geriatric population in Asia 2009 and 2018
  • Exhibit 37: Asia - Year-over-year growth 2019-2023 (%)
  • Exhibit 38: Top 3 countries in Asia
  • Exhibit 39: ROW - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 40: ROW - Year-over-year growth 2019-2023 (%)
  • Exhibit 41: Top 3 countries in ROW
  • Exhibit 42: Key leading countries
  • Exhibit 43: Market opportunity
  • Exhibit 44: Growth in geriatric population 2014-2018 (%)
  • Exhibit 45: Side effects of chemotherapy drugs used for treatment of hairy cell leukemia
  • Exhibit 46: Impact of drivers and challenges
  • Exhibit 47: Drug designations
  • Exhibit 48: Vendor landscape
  • Exhibit 49: Landscape disruption
  • Exhibit 50: Vendors covered
  • Exhibit 51: Vendor classification
  • Exhibit 52: Market positioning of vendors
  • Exhibit 53: AstraZeneca Plc - Vendor overview
  • Exhibit 54: AstraZeneca Plc - Business segments
  • Exhibit 55: AstraZeneca Plc - Organizational developments
  • Exhibit 56: AstraZeneca Plc - Geographic focus
  • Exhibit 57: AstraZeneca Plc - Key offerings
  • Exhibit 58: AstraZeneca Plc - Key customers
  • Exhibit 59: F. Hoffmann-La Roche Ltd. - Vendor overview
  • Exhibit 60: F. Hoffmann-La Roche Ltd. - Product segments
  • Exhibit 61: F. Hoffmann-La Roche Ltd. - Organizational developments
  • Exhibit 62: F. Hoffmann-La Roche Ltd. - Geographic focus
  • Exhibit 63: F. Hoffmann-La Roche Ltd. - Segment focus
  • Exhibit 64: F. Hoffmann-La Roche Ltd. - Key offerings
  • Exhibit 65: F. Hoffmann-La Roche Ltd. - Key customers
  • Exhibit 66: Merck & Co. Inc. - Vendor overview
  • Exhibit 67: Merck & Co. Inc. - Business segments
  • Exhibit 68: Merck & Co. Inc. - Organizational developments
  • Exhibit 69: Merck & Co. Inc. - Geographic focus
  • Exhibit 70: Merck & Co. Inc. - Segment focus
  • Exhibit 71: Merck & Co. Inc. - Key offerings
  • Exhibit 72: Merck & Co. Inc. - Key customers
  • Exhibit 73: Mylan NV - Vendor overview
  • Exhibit 74: Mylan NV - Product segments
  • Exhibit 75: Mylan NV - Organizational developments
  • Exhibit 76: Mylan NV - Geographic focus
  • Exhibit 77: Mylan NV - Segment focus
  • Exhibit 78: Mylan NV - Key offerings
  • Exhibit 79: Mylan NV - Key customers
  • Exhibit 80: Pfizer Inc. - Vendor overview
  • Exhibit 81: Pfizer Inc. - Business segments
  • Exhibit 82: Pfizer Inc. - Organizational developments
  • Exhibit 83: Pfizer Inc. - Geographic focus
  • Exhibit 84: Pfizer Inc. - Segment focus
  • Exhibit 85: Pfizer Inc. - Key offerings
  • Exhibit 86: Pfizer Inc. - Key customers
  • Exhibit 87: Validation techniques employed for market sizing
  • Exhibit 88: Definition of market positioning of vendors
Back to Top
전화 문의
F A Q